On February 6, 2019, CADTH announced a new collaboration with England’s NICE (National Institute for Health and Care Excellence) to offer Parallel Scientific Advice to pharmaceutical companies. Participating pharmaceutical companies will receive advice simultaneously from CADTH and NICE to facilitate evidence generation for the Canadian and English markets.
This new opportunity for Parallel Scientific Advice could be particularly useful for pharmaceutical companies at an early point in the drug development process. The Scientific Advice programs from NICE and CADTH are voluntary, fee-for-service consultations. To get the most out of their services, both CADTH and NICE recommend seeking advice during the planning stages of the main registration efficacy studies.
- For more information on CADTH/NICE Parallel Scientific Advice visit: https://www.cadth.ca/scientific-advice.
- For more information about the NICE Scientific Advice program, please visit: www.nice.org.uk/about/what-we-do/scientific-advice.